December 15, 2004
Genta Announces Sale of 15 Million Shares of Common Stock
December 7, 2004
ASH Presentations Affirm Importance of Genasense® Target in CLL
December 6, 2004
Genasense® Significantly Increases Major Responses in Patients with Advanced Chronic Lymphocytic Leukemia
December 5, 2004
Clinical Trials Show Potential Utility of Biomarkers for Genasense® Activity in Patients with Plasma Cell Disorders
December 5, 2004
Ganite® Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting
December 5, 2004
Genasense® Shown to Enhance the Anti-Lymphoma Activity of Velcade® and Rituxan®
December 4, 2004
Phase 3 Results of Genasense® Plus Dexamethasone in Patients with Advanced Multiple Myeloma Presented at ASH Meeting
December 4, 2004
Phase 2 Study of Genasense® plus Mylotarg® Yields Complete Remissions in Older Patients with Acute Myeloid Leukemia
December 3, 2004
Genta Acquires C-Myb Antisense Drug Clinical-Stage Compound Targets a Key Cancer Control Gene
December 3, 2004
Genta Incorporated Announces Conference Call to Review Corporate Highlights and Data Presented at the Annual Meeting of the American Society of Hematology(2)
December 3, 2004
Genta Incorporated Announces Conference Call to Review Corporate Highlights and Data Presented at the Annual Meeting of the American Society of Hematology
November 29, 2004
Genta's Programs in Blood Cancers Featured in Presentations at the Annual Meeting of the American Society of Hematology
November 26, 2004
Phase 3 Trial of Genasense® in Patients with Advanced Multiple Myeloma Does Not Meet Primary End-point
November 11, 2004
Genasense® Update in Lung Cancer to be Presented at XXII Chemotherapy Foundation Symposium
November 9, 2004
Genta Announces 3rd Quarter 2004 Financial Results
November 8, 2004
Phase 3 Trial of Genasense® plus Chemotherapy in Patients with Advanced Chronic Lymphocytic Leukemia Achieves Primary Endpoint
November 8, 2004
Genta Announces Termination of Genasense® Agreements by Aventis
November 4, 2004
Genta Incorporated Announces Conference Call to Discuss Third Quarter 2004 Earnings
September 22, 2004
Genta to Present at UBS Global Life Sciences Conference
August 3, 2004
Genta Announces 2nd Quarter 2004 Financial Results
July 29, 2004
Genta Incorporated Announces Conference Call to Discuss Second Quarter 2004 Earnings
June 21, 2004
Genta Incorporated Announces Webcast of 2004 Annual Shareholders Meeting
June 7, 2004
Genta Announces Updated Results from its Phase 3 Trial of GenasenseTM for Advanced Melanoma
May 28, 2004
Genta and Aventis Announce Termination of GenasenseTM Expanded Access Program in Melanoma
May 13, 2004
Genta Announces Withdrawal of New Drug Application for GenasenseTM in Melanoma
May 13, 2004
Genta Announces Restructuring to Focus on GenasenseTM Programs
May 4, 2004
Genta Incorporated Announces Conference Call to Discuss ODAC Meeting Outcome
May 3, 2004
FDA Advisory Committee Reviews Genasense<sup>TM</sup> For Use in Advanced Melanoma
April 30, 2004
FDA Posts Briefing Documents for Oncologic Drugs Advisory Committee Meeting on Genasense<sup>TM</sup>
April 29, 2004
Genta Announces 1st Quarter 2004 Financial Results and Highlights
April 27, 2004
Genta Incorporated Announces Conference Call to Discuss First Quarter 2004 Earnings
April 20, 2004
Genta and Aventis Announce GenasenseTM Expanded Access Program for Patients with Advanced Melanoma
April 2, 2004
Genta Incorporated Files Shelf Registration Statement
March 25, 2004
GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research
February 25, 2004
Genta to Present at Lehman Brothers Healthcare Conference
February 17, 2004
Genta to Present at BIO CEO and Investor Conference
February 11, 2004
Genta Reports Fourth Quarter and Year End 2003 Financial Results and Developments
February 6, 2004
Genta and Aventis Announce FDA Acceptance and Priority Review of New Drug Application for GenasenseTM in Advanced Melanoma
February 6, 2004
Genta to Hold Conference Call and Webcast to Discuss Year End and Fourth Quarter 2003 Results
January 27, 2004
Genta Issues Statement Regarding GenasenseTM Agreement with Aventis
January 22, 2004
Genta to Present at U.S. Bancorp Piper Jaffray Healthcare Conference
January 22, 2004
State Treasury/EDA Officials Highlight State Business Incentives With Visit To Genta Incorporated
January 8, 2004
Genta to Present at JP Morgan Healthcare Conference
